EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

The landscape of MHC-presented phosphopeptides yields actionable shared tumor antigens for cancer immunotherapy across multiple HLA alleles

Zaki Molvi iD, Martin G Klatt iD, Tao Dao, Jessica Urraca, David A Scheinberg, Richard J O'Reilly

Journal for ImmunoTherapy of Cancer · 2023

DOI: 10.1136/jitc-2023-006889 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2023. Verfasst von Zaki Molvi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Immunology Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA zakimolvi@gmail.com. Hauptthemen laut MEDLINE: Phosphopeptides, Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, NIGMS NIH HHS, The Aubrey Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Certain phosphorylated peptides are differentially presented by major histocompatibility complex (MHC) molecules on cancer cells characterized by aberrant phosphorylation. Phosphopeptides presented in complex with the human leukocyte antigen HLA-A*02:01 provide a stability advantage over their non-phosphorylated counterparts. This stability is thought to contribute to enhanced immunogenicity. Whether tumor-associated phosphopeptides presented by other common alleles exhibit immunogenicity and structural characteristics similar to those presented by A*02:01 is unclear. Therefore, we determined the identity, structural features, and immunogenicity of phosphopeptides presented by the prevalent alleles HLA-A*03:01, HLA-A*11:01, HLA-C*07:01, and HLA-C*07:02.

Methods

We isolated peptide-MHC complexes by immunoprecipitation from 11 healthy and neoplastic tissue samples using mass spectrometry, and then combined the resulting data with public immunopeptidomics data sets to assemble a curated set of phosphopeptides presented by 96 samples spanning 20 distinct healthy and neoplastic tissue types. We determined the biochemical features of selected phosphopeptides by in vitro binding assays and in silico docking, and their immunogenicity by analyzing healthy donor T cells for phosphopeptide-specific multimer binding and cytokine production.

Results

We identified a subset of phosphopeptides presented by HLA-A*03:01, A*11:01, C*07:01 and C*07:02 on multiple tumor types, particularly lymphomas and leukemias, but not healthy tissues. These phosphopeptides are products of genes essential to lymphoma and leukemia survival. The presented phosphopeptides generally exhibited similar or worse binding to A*03:01 than their non-phosphorylated counterparts. HLA-C*07:01 generally presented phosphopeptides but not their unmodified counterparts. Phosphopeptide binding to HLA-C*07:01 was dependent on B-pocket interactions that were absent in HLA-C*07:02. While HLA-A*02:01 and HLA-A*11:01 phosphopeptide-specific T cells could be readily detected in an autologous setting even when the non-phosphorylated peptide was co-presented, HLA-A*03:01 or HLA-C*07:01 phosphopeptides were repeatedly non-immunogenic, requiring use of allogeneic T cells to induce phosphopeptide-specific T cells.

Conclusions

Phosphopeptides presented by multiple alleles that are differentially expressed on tumors constitute tumor-specific antigens that could be targeted for cancer immunotherapy, but the immunogenicity of such phosphopeptides is not a general feature. In particular, phosphopeptides presented by HLA-A*02:01 and A*11:01 exhibit consistent immunogenicity, while phosphopeptides presented by HLA-A*03:01 and C*07:01, although appropriately presented, are not immunogenic. Thus, to address an expanded patient population, phosphopeptide-targeted immunotherapies should be wary of allele-specific differences.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PhosphopeptidesNeoplasmsHumansAntigens, NeoplasmAllelesHLA-C AntigensHistocompatibility AntigensMajor Histocompatibility ComplexImmunotherapyHLA-A Antigens

Stichwörter der Autor:innen

CD8-positive T-lymphocytesantigen presentationantigensantigens, tumor-associated, carbohydratehematologic neoplasms

Substanzen

PhosphopeptidesAntigens, NeoplasmHLA-C AntigensHistocompatibility AntigensHLA-A Antigens

Autor:innen und Institutionen

  • Immunology Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA zakimolvi@gmail.com.
  • Department of Hematology, Oncology and Tumor Immunology, Charite Universitatsmedizin Berlin, Berlin, Germany.
  • German Cancer Research Center, Heidelberg, Baden-Württemberg, Germany.
  • Berlin Institute of Health at Charité -Universitätsmedizin Berlin, BIH Biomedical 13 Innovation Academy, BIH Charité Clinician Scientist Program, Berlin, Germany.
  • Department of Pediatrics, Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.

ORCID-Profile: Zaki Molvi, Martin G Klatt

Förderung

  • NCI NIH HHS
  • NIGMS NIH HHS
  • The Aubrey Fund
  • Edith Robertson Foundation
  • NIH/NCI Cancer Center Support Grant
  • BIH Charité Clinician Scientist Program
  • NIH NCI
  • Alex's Lemonade Stand Foundation for Childhood Cancer

Zitieren

APA

Molvi, Z., Klatt, M. G., Dao, T., Urraca, J., Scheinberg, D. A., & O'Reilly, R. J. (2023). The landscape of MHC-presented phosphopeptides yields actionable shared tumor antigens for cancer immunotherapy across multiple HLA alleles. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2023-006889

Vancouver

Molvi Z, Klatt MG, Dao T, Urraca J, Scheinberg DA, O'Reilly RJ. The landscape of MHC-presented phosphopeptides yields actionable shared tumor antigens for cancer immunotherapy across multiple HLA alleles. Journal for ImmunoTherapy of Cancer. 2023. doi:10.1136/jitc-2023-006889

BibTeX
@article{Molvi2023,
  author = {Molvi, Zaki and Klatt, Martin G and Dao, Tao and Urraca, Jessica and Scheinberg, David A and O'Reilly, Richard J},
  title = {The landscape of MHC-presented phosphopeptides yields actionable shared tumor antigens for cancer immunotherapy across multiple HLA alleles},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2023},
  doi = {10.1136/jitc-2023-006889}
}
Kostenlos starten →